J&J To Pay States $181M Over Deceptive Risperdal Marketing

Law360, New York (August 30, 2012, 3:17 PM EDT) -- Johnson & Johnson agreed Thursday to pay $181 million to 36 states and Washington, D.C., to resolve claims that it deceptively marketed its antipsychotic drugs Risperdal and Invega in what the states are calling the largest-ever multistate consumer protection settlement with a pharmaceutical company.

Under the terms of consent decrees filed in each of the 37 jurisdictions, J&J agreed to change how it promotes and markets the products and stop distributing unsolicited information describing any off-label or unapproved use of the drug, in addition to handing...
To view the full article, register now.